SCHEMBL4242686

SCHEMBL4242686

O=c1c2ccccc2nc(-c2ccccc2)n1NCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.65
HTT P42858 3/20 0.65
NPSR1 Q6W5P4 3/20 0.65
MAPT P10636 2/20 0.65
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
POLB P06746 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
CYP1A2 P05177 2/20 0.60
CYP3A4 P08684 2/20 0.60
CYP2D6 P10635 2/20 0.60
CYP2C9 P11712 2/20 0.60
CYP2C19 P33261 2/20 0.60
ALDH1A1 P00352 6/20 0.59
RAB9A P51151 2/20 0.59
RECQL P46063 1/20 0.59
TSHR P16473 2/20 0.57
USP2 O75604 1/20 0.57
TP53 P04637 1/20 0.57
ALOX15 P16050 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245035 0.91 EGFR (0.62) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4242390 0.88 ALDH1A1 (0.62) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL13930051 0.84 SMN1; SMN2 (0.68) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4237311 0.83 ALDH1A1 (0.58) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4237651 0.83 SMN1; SMN2 (0.67) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4236185 0.83 SMN1; SMN2 (0.67) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4233360 0.83 ALDH1A1 (0.61) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4244207 0.83 MAPT (0.62) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL14161015 0.82 KMT2A (0.71) LMNAHTTNPSR1MAPTKMT2A
SCHEMBL4237693 0.81 SMN1; SMN2 (0.64) LMNAHTTNPSR1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 LMNA 3751/4885HTT 2966/4885NPSR1 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.